	CT05-GSOP-RF04 7.0	PHASE 1 CLINICAL STUDY INFORMED CONSENT TEMPLATE		01-Jul-2019
Protocol Number: C4591007		ICD Version Date: (Study): Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021		
<input checked="" type="checkbox"/> Study <input type="checkbox"/> Country <input type="checkbox"/> Site	Language: English	Center ID: N/A	Country: N/A	
ICD Derived From: N/A				

Dear Sir/Madam,

Thank you for taking the time to consider if you would like to join this study. We understand that this may be a difficult decision. This consent document can help you make your decision by explaining **what you can expect to happen during this study**, also known as a clinical trial or a research study.

Taking part in this study is **completely voluntary (your choice)**. Take as long as you need to make your decision. You also can choose to take part in the study now, and then change your mind later at any time. Please keep in mind that even if you choose to take part, it may turn out that you do not meet the study's entry requirements.

We encourage you to **have conversations with your family, caregivers, doctors, and study team** about taking part in this study and whether it is right for you. The study team will work with you to answer any questions that you may have about the study. The study team includes the study doctor, nurses, and others who work with the study doctor.

If you choose to take part in this study, **you will be asked to sign and date this consent document** before you start the study to let the study team know your decision.


You will receive a signed and dated copy of this consent document for your records. Please keep this consent document for your reference.

We appreciate that you are thinking of taking part in this study.

Sincerely,

Study Doctor

















090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study): Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 2021	Intro Page: 1 of 1
Protocol No. C4591007 PFIZER CONFIDENTIAL		FDA-CBER-2021-5683-1076670

CONSENT TO TAKE PART IN STUDY

Table of Contents

This Table of Contents describes the different sections of this consent document. Be sure to read through all sections of this consent document before making your decision about whether or not to participate in this study.

	Section	Page
	1. Key study information and contact information	4
	2. Brief summary of this study	5
	3. What is the purpose of this study?	7
	4. How long will I participate in this study?	8
	5. How many adults and children will take part in this study?	8
	6. What will happen during this study?	9
	7. Are there any special instructions to follow for this study?	14
	8. What are the possible risks and discomforts of this study?	14
	9. What are the possible benefits of this study?	17
	10. What other choices do I have if I do not want to join this study?	17
	11. What happens if I am injured during this study?	17
	12. What if I join this study and then changes my mind?	17
	13. What will I have to pay for if I take part in this study?	18
	14. Will I be paid for taking part in this study?	18
	15. What will happen to my personal information?	18
	16. Where can I find additional information about this study or the study results?	18

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

CONSENT TO TAKE PART IN STUDY




17. Signatures

19



Privacy Supplement

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 3 of 22
---	--	--------------------------------

FDA-CBER-2021-5683-1076672

CONSENT TO TAKE PART IN STUDY

1. Key Study Information and Contact Information

The study team will address any questions, concerns or complaints you may have before, during and after you complete the study. The study team includes the study doctor, nurses, and other personnel who work with the study doctor.

Phone numbers for the study team are listed below under “Study Site Contact Information.” **You will be given a card with important emergency contact information, including a 24-hour number.** Please show this card to any doctor, nurse or other health care provider if you seek emergency care while they are taking part in this study. This card includes information about the study that will help them treat you.

If you have any general questions about your rights as a study participant, or would like to obtain information from, offer suggestions to, or speak with someone not directly involved in the study, you may contact **[For the site-level ICD, include as appropriate: the Institutional Review Board or the Independent Ethics Committee, patient rights advocate, and/or bioethicist]** listed below.

Name of Study: **A Phase 1, Open-Label Dose-Finding study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate against COVID-19 in Healthy Children and Young Adults**

Sponsor Consent Version Number (Study/Country/Site): **01 / 00 / 00**

[Institution] Study Number:

Sponsor Study Number: **C4591007**

Name of Company Sponsoring the Study: **BioNTech. Study conducted by Pfizer**

Name of Principal Investigator (Study Doctor):

Study Site Contact Information:

Contact Person:

Address:

Phone Number (Normal Business Hours):

Phone Number (Off-Hours or Emergency):


[Complete the following entries for the site-level ICD as appropriate.]

[Institutional Review Board or Independent Ethics Committee] Contact Information:

Contact Person:

Address:

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 4 of 22
---	--	-------------------------

FDA-CBER-2021-5683-1076673

CONSENT TO TAKE PART IN STUDY

Phone Number:

Patient Rights Advocate:

Contact Person:

Address:

Phone Number:

Bioethicist:

Contact Person:

Address:

Phone Number:

2. Brief Summary of this Study


This is a research study involving both Pfizer and BioNTech. Pfizer and BioNTech are separate companies who are cooperating to perform this study. Pfizer is responsible for conducting this study. BioNTech is the regulatory sponsor of this study. Funding for this study is provided by BioNTech and Pfizer and [study doctor/institution] will be paid to conduct this study.

A new respiratory disease appeared in Wuhan, China in December 2019, and has since rapidly spread to many other countries around the world. In January 2020, the cause of this disease was found to be a new Coronavirus; and the disease it causes was named COVID-19 (Coronavirus disease 2019). Since then, many companies around the world have quickly started to look for treatments and ways to prevent COVID-19.

Vaccines help your body to produce antibodies to help you to fight off a disease. This research study involves an investigational vaccine to prevent COVID-19, that will be given to volunteers. The vaccine is given by injection. The study will also test the study vaccine at different dose levels (amount of vaccine).


These vaccines do not contain the whole virus, or the part of the virus that can make you ill, instead the vaccines are made up of part of the virus's genetic code, surrounded by fatty particles called lipids. They use person's own cells' protein making machinery to produce some, or all, of the spike protein seen on the outside of the virus. This spike protein, made by the person's own body, may help the body to produce antibodies to fight against COVID-19. We will check the level of antibodies you make by taking blood samples and testing them.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 5 of 22 FDA-CBER-2021-5683-1076674
---	--	--

CONSENT TO TAKE PART IN STUDY

Coronavirus



Up until June 2021, the safety of BNT162b2 has been studied in clinical trials that have included about 28,500 people who have received at least one dose of the vaccine. In addition, since the vaccine has been approved for emergency use or received a conditional marketing authorization in many countries, by the end of April about 400 million doses have been distributed. Based on available data, the following risks have been determined to be caused by BNT162b2 vaccine: Injection site pain, injection site swelling, fatigue (tiredness), increased body temperature (fever), chills, headache, diarrhea, joint aches, muscle aches, feeling sick (nausea), being sick (vomiting), injection site redness, enlarged lymph glands, allergic reaction (symptoms may include rash, itching, hives, and swelling of the face or lips), decreased appetite, lethargy, sweating and night sweats, pain in arm, feeling weak or unwell, and severe allergic reaction (anaphylaxis).

Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received BNT162b2. Cases have mainly been reported in males under 30 years of age and following the second vaccination. Symptoms include: Chest pain, shortness of breath, or feelings of having a fast-beating, fluttering or pounding heart. As a precaution, you should seek medical attention right away if you have any of those symptoms after receiving the vaccine. The chance of having this occur is very low.


Although not seen to date, it cannot yet be ruled out that the study vaccine could make a later COVID-19 illness more severe.

You are being asked to take part in a research study that will investigate whether the investigational (study) vaccine to prevent COVID-19 is safe, tolerable and causes immune response to the virus causing COVID-19. The vaccine is given by an injection.

Overall, the study has two Phases;

- In Phase 1 we will study how safe the vaccine is and the immune response it produces at different doses. We will then choose a dose level for Phase 2/3.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 6 of 22 FDA-CBER-2021-5683-1076675
---	--	--

CONSENT TO TAKE PART IN STUDY

- In Phase 2/3 we will study how safe the vaccine is and the immune response it produces in a larger number of children and young adults.

For this part of the study, this consent is for **Phase 1 Lower Dose Evaluation** participants and you are being asked to see if you would like to take part in this phase.

- In the Phase 1 of the study, all participants will receive the active study vaccine. In this Phase 1, up to two different dose levels (amount of vaccine) will be studied. You will be assigned to one of the two dose level groups.
- From the Phase 1, we will choose a dose for the Phase 2/3. In this part of the study, we will study how safe the vaccine is and the immune response it produces in a larger number of children and young adults.

You are being asked to be in this research study because you are healthy and meet the age requirement for this study.

This study is different from your regular medical care. The purpose of regular medical care is to improve or otherwise manage your health, but the purpose of research is to gather information to advance science and medicine and does not replace your regular medical care. If you need medical care during your time in the study, you should contact your regular provider and inform the study team, as described later in this document.


Taking part in this study is voluntary (your choice). There is no penalty or change to you or your regular medical care if you decide not to participate. You can choose to take part in the study now, and then change your mind later at any time without losing any benefits or medical care to which you are entitled. We encourage you to have conversations with your family, caregivers, doctors, and study team about taking part in this study and whether it is right for you. The study team will work with you to answer any questions that you may have about the study.

You will receive a signed and dated copy of this consent document for your records. Please keep this consent document for your reference.

3. What is the purpose of this study?

The World Health Organization (WHO) has declared COVID-19 to be a pandemic (a disease that has spread all over the world and is affecting lots of people); finding a vaccine to prevent COVID-19 is an urgent need. To test this investigational vaccine as quickly as possible, this study will be conducted in several steps, which are described below. Currently, the authorized dose of the vaccine in adolescents and young adults 12 years and older is 30 µg. To reduce the reactions that can occur soon after vaccination and to determine whether similar immune responses are produced, additional lower dose levels of the vaccine (3 µg and 10 µg) will be evaluated in ages 5 to 30 years. The steps in the study are detailed below.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 7 of 22
---	--	--------------------------------

FDA-CBER-2021-5683-1076676

CONSENT TO TAKE PART IN STUDY

You are being asked to take part in the **Phase 1 Lower Dose Evaluation** step of the study.

Phase 1 Lower Dose Evaluation will be carried out in 3 age groups. **Every participant in this Phase will receive two injections of the active study vaccine.** The following age groups will take part in this step of the study:

- 16 to less than 30 years of age,
- 12 to less than 16 years of age, and
- 5 to less than 12 years of age.

The remaining step of the study will be the **Phase 2/3 Lower Dose Evaluation.** In this part we will use a dose level selected from the Phase 1 part of the study. This step of the study will collect information from a larger number of children and young adults about the safety of the vaccine and the amount of antibodies produced by the vaccine. In this part of the study all participants will receive active vaccine. The age groups taking part in this step of the study will be:

- 16 to less than 30 years of age,
- 12 to less than 16 years of age, and
- 5 to less than 12 years of age.

Please note that this part of the original study called **Phase 1 Dose Finding has been completed.** There were 3 age groups in this part and the study looked at up to 3 dose levels in each age group. The children in this part of the study were:

- 5 to less than 12 years of age,
- 2 to less than 5 years of age, and
- 6 months to less than 2 years of age.

Phase 2/3 Selected Dose is currently ongoing, and the dose level was selected from the Phase 1 part of the study. This step of the study will collect information from a larger number of children about the safety of the vaccine and the amount of antibodies produced by the vaccine. In this Phase, all participants will receive either active vaccine or placebo. The children in this step of the study will be:


- 5 to less than 12 years of age,
- 2 to less than 5 years of age, and
- 6 months to less than 2 years of age.

4. How long will I participate in this study?

You will be in this study for about 7 months.

5. How many adults and children will take part in this study?

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 8 of 22 FDA-CBER-2021-5683-1076677
---	--	--

CONSENT TO TAKE PART IN STUDY

This consent is for **Phase 1 Lower Dose Evaluation** and there will be about approximately 96 children less than 16 years old, and about 64 participants 16 to less than 30 years of age taking part in this Phase.

The total number of adults and children taking part in the study will depend on the results seen during the study.

This study will use competitive enrollment. This means that when a certain number of people have enrolled in the study from all study sites combined, no one else will be allowed to participate. So, it is possible that you may not be allowed to join the study.

6. What will happen during this study?

Before any study procedures begin, or before you begin preparing for the study, you will be asked to read and sign and date this consent document.

After signing this consent document, the study doctor will check if you meet all the requirements to take part in this study. If you do not meet the requirements, you will not be able to take part in the study and the study doctor will explain why this is the case. Similarly, if you qualify to take part in this study, the study doctor will explain this as well.

Study Vaccines

Once the study doctor has confirmed that you meet the study requirements, you will be assigned to a dose-level group for the study vaccine.

Phase 1 Lower Dose Evaluation of the study is an “open-label dose-finding phase”, which means in this phase all participants will receive active study vaccine.

In this phase, either 1 or two dose levels of the study vaccine will be studied depending on the age of the participant. There will be 32 participants in each age group that will be given each dose level.

Age of child/adult taking part	3 µg Dose level	10 µg Dose level
5 to less than 12 years of age	<input checked="" type="checkbox"/>	
12 to less than 16 years of age	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
16 to less than 30 years of age,	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

represents 32 participants

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

CONSENT TO TAKE PART IN STUDY


You will be given either the 3 µg dose or the 10 µg dose. You will have a 50:50 chance of getting either dose. The dose level will be chosen by chance by a computer and neither you nor the study team has any influence over this.

The vaccine will be given to you through an injection into the muscle in their upper arm. Each participant will receive two injections of vaccine, approximately three weeks apart. On the days you receive the vaccine injection, you will be asked to wait at the study site for at least 30 minutes for observation after they receive vaccine.

Overview of Study Procedures and Assessments

The table below lists the tests and procedures or assessments that you will have done at each visit. It is important that you attend each visit on the day that your research study team arranges for you. You will have the following tests, procedures or assessments during this study. In addition to the visits listed, your study doctor may ask you to come in for extra visits if necessary, to protect your well-being.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 10 of 22
---	--	---------------------------------

FDA-CBER-2021-5683-1076679

CONSENT TO TAKE PART IN STUDY

For the participants taking part in **Phase 1 Lower Dose Evaluation**, the study doctor or nurse will perform following assessment and procedures:

Visit Number	1	2	3	4	5
Visit Description and Visit Timing	Study Vaccine 1 Visit	Study Vaccine 2 Visit	7-Day Follow-up Visit	1-Month Follow-up Visit or phone call	6-Month Follow-up Phone Call
Review and sign informed consent document	X				
Ask about medical history as well as date of birth, sex, race and ethnicity	X				
Measure pulse rate, respiratory rate, blood pressure, and body temperature	X	X			
Perform a physical exam, including measurement of height and weight (height at weight information will be collected at 1st visit only).	X	X			
If you are female and if needed, you will be asked to provide a urine sample for a pregnancy test	X	X			
If needed, will discuss the use of appropriate birth control with you	X	X	X	X	
Ask about medications you are currently taking		X	X	X	X
Ask about any other vaccines you have been given	X	X	X	X	X
Check you meets all the study requirements	X	X			
Take a nasal swab for the detection of virus causing COVID-19	X	X			
Collect blood sample (~20 mL) to test antibody levels	X	X	X		
Give vaccine injection in your arm and observe for 30-min following injection	X	X			
You will be shown/reminded how to use the e-diary or assist you to download an app, thermometer and caliper (measuring device)	X	X			
You will be asked to complete vaccination e-diary for 7 days to record potential side effects following each vaccination	X	X			
Ask how you are feeling	X	X	X	X	X

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

CONSENT TO TAKE PART IN STUDY

Description of Study Procedures and Assessments

Biological Samples

The following biological samples will be taken in this study. You must provide these samples in order to take part in this study. The samples may be stored in a facility located in a different country from your study site.

Your blood and nasal samples will be used only for scientific research. Each sample will be labeled with a code so that the laboratory workers testing the samples will not know who you are. Some of the samples may be stored for future testing and may be kept for up to 15 years after the study ends, at which time they will be destroyed. In addition to testing for this study, any samples left over after the study is complete may be used for additional research related to the development of product. No testing of your DNA will be performed.

You may request that your samples, if they can be identified, be destroyed at any time. Any data already collected from those samples will still be used for the study. The samples will remain the property of BioNTech/Pfizer and may be shared with other researchers as long as confidentiality is maintained. No testing of your DNA will be performed. You will not be told of additional tests, nor will you receive results of any of these tests.

Blood Samples for antibody testing:

You will have blood taken three times during the planned study visits.

Each blood sample will be approximately 20 mL and will be collected using a needle.

Your blood samples will be used to test if you already had antibodies against the coronavirus that causes COVID-19 when you enrolled in the study and may be used to test antibody levels after vaccination.


Nasal Swabs for detection of coronavirus causing COVID-19:

You will have nasal swab collected from your nose two times during the planned study visits. A swab (which looks like a Q-tip) will be inserted into your nose to collect any fluid or mucus. These samples will be tested to detect the presence of coronavirus causing COVID-19. Results of nasal swabs at Visit 1 and Visit 2 will be provided to your study doctor, however, this will take some time so you should not rely on this information for your medical treatment.

Urine Samples:

If you are female and able to have children in the opinion of study doctor, you will need to provide urine sample for pregnancy testing before you get the study vaccine injection. If you have a positive urine pregnancy test result, the study doctor will tell you and you will not be able to participate in the study.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 12 of 22 FDA-CBER-2021-5683-1076681
---	--	---

CONSENT TO TAKE PART IN STUDY

E-Diary:

At Visit 1, the study team will explain what you need to do and show you how to fill in an electronic diary (or e-diary). We will either give you a device (like a mobile phone) or ask you to download an application (app) to your smart phone if you have one. The device/app is secure, and your confidentiality will be maintained. You will also be given a thermometer and a measuring device (caliper).

The e-diary will prompt you to answer questions about how you are feeling after receiving the study vaccination. You will be instructed by the study team to complete the e-diary every evening for 7 days after each injection. Day 1 of the e-diary completion will begin on the evening you receive the injection and the following 6 days (7 days in total). You will use the thermometer to measure your oral temperature (under your tongue). You will then enter the temperature reading into the e-diary. The measuring device will be used to measure the size of any redness or swelling on your arm where the injection was given. You will need to enter these measurements in the e-diary.

The e-diary will also ask other questions about potential side effects you may have after the injection. If you have any severe symptoms after vaccination, you should contact your study doctor and the study doctor or nurse may schedule an extra unplanned visit to evaluate you.

It is very important that you complete the e-diary regularly as instructed. If this is not completed, the study doctor or nurse will contact you to check how you are.

What happens if I have a positive nose swab test result after Visit 1 but before Visit 2?

If you have any potential COVID-19 symptoms with a positive nose swab test result after visit 1 and before visit 2, you will not be given the second study injection. You will however be asked to stay in the study so we can collect safety information.


Leaving the Study Early

You may withdraw from the study at any time at your own request. You could also be withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or administrative reasons. If you decide to leave the study, you would be asked why you would like to withdraw.

After the study

The study vaccine is available only during this study and not after the study is over.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 13 of 22
---	--	--------------------------

CONSENT TO TAKE PART IN STUDY

7. Are there any special instructions to follow for this study?

It is important that you follow all the instructions given to you by the study nurse or doctor and tell them if:

- You do not understand anything about the study
- You will not be able to comply with the study requirements
- There are changes in your health
- Your e-diary device or APP is not working properly
- You take any new medications or receive any other vaccines
- You are going away for a long period
- You wish to take part in another research study
- You previously took part in this study, have been in any other study in the past 28 days, or are currently involved in any other study
- Notify the study team if you move and provide your new contact information.

8. What are the possible risks and discomforts of this study?

Any research has some risks, which may include negative effects that could make you unwell or uncomfortable and even potentially be serious or life-threatening. All research participants taking part in the study will be watched carefully for any negative effects; however, the study team does not know all the effects that the study vaccine may have on you.

If you take part in this study, the most likely risks or discomforts are discussed below.


It is important that you report to the study team all symptoms and side effects as soon as they occur. Phone numbers for the study team are listed in [Section 1] of this consent document.

Up until June 2021, the safety of BNT162b2 has been studied in clinical trials that have included about 28,500 people who have received at least one dose of the vaccine. In addition, since the vaccine has been approved for emergency use or received a conditional marketing authorization in many countries, by the end of April about 400 million doses have been distributed.

Based on the clinical study results, and information gathered during general use, the following risks have been determined to be caused by BNT162b2 vaccine:

Very common (occurring in more than 1 in 10 people): injection site pain, injection site swelling, fatigue (tiredness), increased body temperature (fever, more common after the second dose), chills, headache, diarrhea, joint aches, and muscle aches.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 14 of 22 FDA-CBER-2021-5683-1076683
---	--	--

CONSENT TO TAKE PART IN STUDY

Common (between 1 in 10 and 1 in 100 people): feeling sick (nausea), being sick (vomiting), and injection site redness.

Uncommon (between 1 in 100 and 1 in 1,000 people): enlarged lymph glands, allergic reactions (symptoms may include rash, itching, hives), decreased appetite, lethargy, sweating and night sweats, pain in arm, and feeling weak or unwell.

Rare (between 1 in 1,000 and 1 in 10,000 people): swelling of the face or lips.

Frequency that cannot be estimated from available data: severe allergic reaction (anaphylaxis).

Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received BNT162b2. Cases have mainly been reported in males under 30 years of age and following the second vaccination, however, there have been some cases reported in older males and females as well as following the first vaccination. The chance of having this occur is very low and, in most of these people, symptoms began within a few days to a week following vaccination. As a precaution, you should seek medical attention right away if you have any of the following symptoms after receiving the vaccine:

- Chest pain
- Shortness of breath
- Feelings of having a fast-beating, fluttering, or pounding heart

Please also notify study staff, when appropriate, if you have any of these symptoms as you may need to come in for an assessment.

Whilst some severe cases have been reported, most cases have been associated with full resolution of symptoms in the short term, however, long-term follow-up is limited. It is not known whether the risk of myocarditis or pericarditis is increased following additional doses of the vaccine, e.g. following a booster dose.


If you have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart) previously, please tell your study doctor.

As in all research studies, the COVID-19 vaccine may involve risks that might be expected based on results from studies of similar vaccines, as well as risks that are currently unknown.

Therefore, it is important that you report all symptoms and side effects that you experience as soon as they occur, whether or not you think they are caused by the study vaccine.

Due to the way in which the study vaccines are made, they cannot cause COVID-19 disease.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 15 of 22 FDA-CBER-2021-5683-1076684
---	--	--

CONSENT TO TAKE PART IN STUDY

If you catch COVID-19 disease, could the vaccine make it worse?

For some other vaccines tested in animals against similar viruses (but not the coronavirus that causes COVID-19), there have been reports of the illness being more severe in the animals that received the vaccine than in those that did not. So far this has not been seen with BNT162b2. It remains important for you to contact your study doctor if you develop symptoms that might be caused by COVID-19 (for example, fever, cough, shortness of breath).

Risks from Study Procedures

Risks and possible discomforts you might have from the study procedures include:

- **Blood Samples:** The risks and possible discomforts involved in taking blood include pain from inserting the needle, or less often, swelling, bruising, or infection around the vein where the blood is collected. You may feel dizzy or may faint. If you have a previous history of feeling dizzy or fainting during blood sample collection you should talk to the study doctor.
- **Nasal Swabs:** The risks and possible discomforts involved in taking nasal swabs may include pain or general discomfort. Sometimes it may cause the nose to bleed.

Pregnancy-Related Risks; Use of Birth Control

If you are currently pregnant, plan to become pregnant, or are breastfeeding a child, you should not join this study. If you are male, you should not father a baby while taking part in this study.


If you are able to have children and are sexually active, you must use birth control consistently and correctly for the duration of the study including at least 28 days after you receive your last injection. This applies to male participants as well as female participants who take part in the research study.

The study doctor will discuss with you the methods of birth control that you should use while in this research study. The study doctor will help you select the method that is appropriate for you. The study doctor will also check that you understand how to use the birth control method and may review this with you at each research study visits.

Birth control methods, even when used properly are not perfect. If you or your partner becomes pregnant during the research study, or if you want to stop birth control during the research study, you should tell the study doctor immediately. You may be withdrawn from the research study if you stop using birth control or become pregnant.

If abstinence (not having sexual intercourse at all) is your current lifestyle, and both you and the study doctor agree that it is your selected method of contraception, you must continue not to have sexual intercourse for the duration of your participation in this study.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 16 of 22 FDA-CBER-2021-5683-1076685
---	--	--

CONSENT TO TAKE PART IN STUDY

Pregnancy Follow-up

If you or your partner become pregnant during the study, up until 28 days after your last study injection, please tell the study doctor **immediately**. Please also tell the doctor who will be taking care of you/your partner during the pregnancy that you took part in this study. The study doctor will ask if you/your partner or their pregnancy doctor is willing to provide updates on the progress of the pregnancy and its outcome. If you/your partner agree, this information will be provided to the BioNTech/Pfizer for safety follow-up.

9. What are possible benefits of this study?

Vaccination with BNT162b2 has been shown to be effective in preventing COVID-19 in the groups of people already studied, but not yet at this dose level. Because of this, you still need to follow local recommendations about how to avoid COVID-19 (for example, social distancing and mask use). In addition, information learned from the research study may help other people in the future.

10. What other choices do I have if I do not want to join this study?

This study is for research purposes only. The only alternative is to not take part in this study.

11. What happens if I am injured during this study?

For mandatory research injury language, [<click here>](#) (retain this link in the study-level ICD). The country-specific research injury language must be included verbatim in the country-level ICD.

12. What if I join this study and then change my mind?


You are free to withdraw from this research study at any time. Tell the study doctor if you are thinking about this so you may end the research study in the safest way. The research study team will also tell you if new information is learned that could change your mind about continuation in this research study. Your decision will not affect the medical care you receive, and you will not lose any benefits to which you would otherwise be entitled.

While you are participating, the study team will tell you in a timely manner if new information is learned during the course of the study that could change your mind about continuing. If you decide to withdraw from the study, you may be asked to continue to participate in the study procedures even though you would no longer be given the study vaccine.

If you continue with the follow-up part of the study, information about your health will continue to be collected as described in [\[Section 6\]](#).

If you decide to stop participating in this study, you must notify the study doctor. The study team will explain what other procedures or discussions would occur.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 17 of 22 FDA-CBER-2021-5683-1076686
---	--	---

CONSENT TO TAKE PART IN STUDY

Sometimes the study doctor or BioNTech/Pfizer may decide to take you out of the study (even if you do not agree) if:

- You are unable or unwilling to follow the instructions of the study team;
- The study doctor decides that the study is not in your best interest or that you are no longer eligible to participate; or
- The study is stopped by the BioNTech/Pfizer, the institutional review board (IRB) or independent ethics committee (IEC) (a group of people who review the study to protect your rights), or by a government or regulatory agency.

The study team will give you a **Privacy Supplement**, which is considered part of this consent document. It describes what happens to your personal information (including your biological samples) and how it may be used if you withdraw from the study.

13. What will I have to pay for if I take part in this study?

You will not need to pay for study vaccine, study-related procedures, or study visits.

14. Will I be paid for taking part in this study?

You will not receive any payment for taking part in this study. However, for each visit you complete, you will be reimbursed by the study site to cover reasonable expenses (for example, parking, meals, travel) that you have as a result of taking part in this study. You will be reimbursed by [enter, as applicable, method of reimbursement; amounts; and reimbursement schedule; note whether receipts are required].]

BioNTech/Pfizer may use information resulting from the study to develop products or processes from which it may make a profit. There are no plans to pay you or provide you with any products developed from this study. BioNTech/Pfizer will own all products or processes that are developed using information from the study.

15. What will happen to my personal information?


<[Click here](#)> for language to be inserted into this section. This text must be inserted **verbatim**. Any requested changes must be approved by Clinical Development Legal. Note that the Privacy Supplement follows this consent document, after the signature section.

16. Where can I find additional information about this study or the study results?

A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.]

The study results, when available, may also be found on www.pfizer.com and <https://www.clinicaltrialsregister.eu/>.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 18 of 22 FDA-CBER-2021-5683-1076687
---	--	--

CONSENT TO TAKE PART IN STUDY

In addition, a plain summary of the study results will be made available in the EU database at [insert link to the database]. This information will be provided no matter what the study's outcome. To the extent possible, you will be able to access these summaries in the EU database soon after they become available using the following EU trial number for the study: [insert trial number].

These websites are in English only. If you need assistance understanding these Web sites, please ask a member of the study team.

BioNTech/Pfizer will provide the study doctor with information about the study results when all participants have completed the study. At that time, certain of your individual study results may be given to you or your doctor (if different from the study doctor) in accordance with applicable law, but will not be given to your family, your employer or any insurance company.

If any exploratory research is done, it may not be possible to link any results from that exploratory research to specific individual, including you. BioNTech/Pfizer does not plan to return information from any exploratory research to you, the study doctor, or your doctor (if different from the study doctor).

17. Signatures

The column for subject initials in the table below may be removed if not required by the IRB/IEC, regulatory agencies, and/or other similar reviewers.

Agreement to Participate and to Process Data	Initials
1. I confirm I have read (or, if I cannot read, a study team member has read to me) and understand this consent document for the study described above and have had the opportunity to ask questions. I have had enough time to review this consent document. I also have had an opportunity to ask about the details of the study and to decide whether or not I want to participate.	
2. I have read and understand the Privacy Supplement. I understand that taking part in the study will require the processing (including collection, use, transfer, storage, analysis and reporting) of my personal information, as explained in the Privacy Supplement. I understand and agree to the processing of my personal information within and outside my country of residence for health care, medical research and/or regulatory purposes.	
3. I understand that taking part is voluntary and that I am free to stop taking part in this study or to withdraw my consent to the processing of my personal information at any time. I do not	

CONSENT TO TAKE PART IN STUDY

<p>need to give any reason and my regular medical care and legal rights will not be affected. However, even if I withdraw my consent to processing, my personal information held at that time may be kept to comply with laws and regulations and to maintain the integrity of the study. I also understand that my biological samples may not be able to be destroyed because they may no longer be traceable to me, may have already been used, or may have been given to a third party.</p>	
<p>4. I agree to the study team accessing my medical history, including information from medical records and test results and any medical treatment I receive during the course of the study, and if necessary, contacting my doctor or any other health care providers treating me for access to such information.</p>	
<p>5. I understand that the BioNTech/Pfizer and/or others working with or on behalf of the BioNTech/Pfizer, institutional review boards (IRBs) or independent ethics committees (IECs), and regulatory agencies may need access to personal information about me generated at the study site or collected by the study team for the study and any other research. I agree that they may have access to my personal information.</p>	
<p>6. I do not give up any of my legal rights by signing this consent document. I have been told that I will receive a signed and dated copy of this document.</p>	
<p>7. I agree for to take part in the study described in this document.</p>	

In the section below, the term “legally acceptable representative” should be replaced with the term required per local regulation (country-level).

Signature Lines to be Included:

Printed name of participant

Signature of participant
(If no legally acceptable representative is used)

Date of signature[§]

§Participant must personally date their signature.

CONSENT TO TAKE PART IN STUDY

Person Obtaining Consent:

Printed Name of the Person Conducting the
Consent Discussion


Signature of the Person Conducting the

Date of signature

Consent Discussion †

†The investigator, or an appropriately qualified and trained person designated by the investigator to conduct the informed consent process, must sign and date the consent document during the same discussion when the participant signs the consent document.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)


	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 21 of 22
---	--	---------------------------------

FDA-CBER-2021-5683-1076690

CONSENT TO TAKE PART IN STUDY

For mandatory country-specific data privacy language to be inserted in this Privacy Supplement, [<click here>](#) (retain this link in the study-level ICD). The country-specific data privacy language must be included verbatim in the country-level ICD. Any requested changes must be approved by Clinical Development Legal.

090177e197c39a58\Approved\Approved On: 09-Aug-2021 16:14 (GMT)

	CT05-GSOP-RF04 7.0 Phase 1/2/3/4 Clinical Study Informed Consent Template (01-Jul-2019) TMF Doc ID: 173.13 (Study); 173.07 (Country/Central); 173.23 (Site) Sponsor Consent Version Date (Study):Phase 1 Lower Dose Evaluation (Adult) V1 09 Aug 2021 Protocol No. C4591007 PFIZER CONFIDENTIAL	Page: 22 of 22
---	--	---------------------------------

FDA-CBER-2021-5683-1076691